Rapport Therapeutics (NASDAQ:RAPP) COO Cheryl Gault Sells 2,014 Shares of Stock

Rapport Therapeutics, Inc. (NASDAQ:RAPP) COO Cheryl Gault sold 2,014 shares of the business’s stock in a transaction dated Thursday, March 5th. The shares were sold at an average price of $28.93, for a total value of $58,265.02. Following the completion of the transaction, the chief operating officer directly owned 169,914 shares of the company’s stock, valued at approximately $4,915,612.02. This trade represents a 1.17% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Rapport Therapeutics Trading Up 1.0%

Shares of RAPP stock opened at $30.54 on Tuesday. Rapport Therapeutics, Inc. has a twelve month low of $7.73 and a twelve month high of $42.27. The stock has a market cap of $1.46 billion, a P/E ratio of -11.27 and a beta of 1.50. The stock has a 50 day moving average of $28.16 and a 200 day moving average of $26.76.

Analyst Upgrades and Downgrades

Several research firms recently commented on RAPP. Wall Street Zen upgraded shares of Rapport Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, February 28th. TD Cowen restated a “buy” rating on shares of Rapport Therapeutics in a research note on Monday. Wells Fargo & Company started coverage on Rapport Therapeutics in a report on Monday, February 2nd. They issued an “overweight” rating and a $43.00 price target for the company. Citigroup reissued a “market outperform” rating on shares of Rapport Therapeutics in a report on Thursday, January 8th. Finally, HC Wainwright upped their target price on Rapport Therapeutics from $34.00 to $40.00 and gave the stock a “buy” rating in a research note on Tuesday, December 9th. Eight equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $50.80.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. Strs Ohio boosted its holdings in Rapport Therapeutics by 23.5% in the 3rd quarter. Strs Ohio now owns 2,100 shares of the company’s stock worth $62,000 after buying an additional 400 shares during the last quarter. Russell Investments Group Ltd. raised its holdings in shares of Rapport Therapeutics by 56.9% during the fourth quarter. Russell Investments Group Ltd. now owns 2,282 shares of the company’s stock valued at $69,000 after acquiring an additional 828 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Rapport Therapeutics by 64.1% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,316 shares of the company’s stock valued at $70,000 after acquiring an additional 905 shares during the last quarter. Meeder Asset Management Inc. purchased a new position in shares of Rapport Therapeutics in the fourth quarter valued at approximately $37,000. Finally, Creative Planning lifted its position in shares of Rapport Therapeutics by 12.8% in the third quarter. Creative Planning now owns 11,959 shares of the company’s stock valued at $355,000 after acquiring an additional 1,357 shares in the last quarter.

About Rapport Therapeutics

Rapport Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for patients with cancer. The company leverages a proprietary discovery engine to identify novel tumor-associated antigens and develop tailored biologic and small-molecule candidates designed to modulate key oncogenic pathways. With a pipeline comprising multiple preclinical and early clinical assets, Rapport is committed to advancing precision medicine approaches and addressing unmet needs in oncology.

Rapport’s discovery engine combines high-throughput screening, molecular profiling and in vivo validation to accelerate the progression of lead candidates from the laboratory to clinical evaluation.